Mereo BioPharma Group Stock Forecast

MREO's stock price has decreased by -87.72% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

According to 8 analysts polled by S&P Global, Mereo BioPharma Group stock has a consensus rating of "Buy" and an average price target of $1.73. The average 1-year stock price forecast is 452.36% higher than the current stock price, while the lowest is $0.50 (+59.64%) and the highest is $2.98 (+851.47%).

Price Target: $1.73 (+452.36%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$0.50	$1.73	$1.48	$2.98
Change	+59.64%	+452.36%	+372.54%	+851.47%

Analyst Ratings

The average analyst rating for Mereo BioPharma Group stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Dec '25	Jan '26	Feb '26	Mar '26	Apr '26	May '26
Strong Buy	4	4	4	4	4	4
Buy	2	2	2	1	1	1
Hold	2	1	1	3	3	3
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	8	7	7	8	8	8

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Kate Dellorusso LifeSci Capital	LifeSci Capital	Hold Maintains n/a	Hold	Maintains	n/a	n/a	May 12, 2026
Gil Blum Needham	Needham	Buy Maintains $3	Buy	Maintains	$3	+857.85%	May 12, 2026
Kristen Kluska Cantor Fitzgerald	Cantor Fitzgerald	Buy Maintains $3	Buy	Maintains	$3	+857.85%	May 12, 2026
Priyanka Grover J.P. Morgan	J.P. Morgan	Hold Maintains n/a	Hold	Maintains	n/a	n/a	Mar 26, 2026
Julian Harrison BTIG	BTIG	Buy Maintains $1	Buy	Maintains	$1	+219.28%	Mar 20, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

1.17M

from 500.00K

133.67%

from 500.00K

Revenue Next Year

19.48M

from 1.17M

1,567.31%

from 1.17M

EPS This Year

n/a

from -

EPS Next Year

n/a

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	49.37M	-	10.00M	-	500.00K	1.17M
Revenue Growth	-	-	-	-	-	133.67%
Gross Profit	25.13M	1.15M	7.43M	-	367.00K	1.17M
Gross Margin	50.89%	-	74.26%	-	73.40%	100.00%
Operating Income	-28.35M	-52.70M	-27.14M	-45.72M	-38.26M	-40.28M
Net Income	17.23M	-42.22M	-29.47M	-43.25M	-41.88M	-32.06M
Free Cash Flow	-9.08M	-32.74M	-14.17M	-21.50M	-17.92M	26.02M
No. Analysts	-	-	-	-	-	6

Revenue Forecast

Revenue	2026	2027	2028
High	7.0M
Avg	1.2M
Low	n/a

Revenue Growth

Revenue Growth	2026	2027	2028
High	1,302.0%
Avg	133.7%
Low	-100.0%

EPS Forecast

EPS	2026	2027	2028
High	-
Avg	-
Low	-

EPS Growth

EPS Growth	2027	2028
High	-
Avg	-
Low	-